Evidence map›Paper›PMID 28911655›Full record

ArticleJournal of food and drug analysis2017

Therapeutic effects of D-aspartate in a mouse model of multiple sclerosis.

Sanaz Afraei, Antimo D'Aniello, Reza Sedaghat, Parvin Ekhtiari, Gholamreza Azizi, Nakisa Tabrizian, Laura Magliozzi, Zahra Aghazadeh, Abbas Mirshafiey

Open access · hybridAbstract read
In one paragraph

Article in Journal of food and drug analysis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Recent progress in microbial production of D-aspartate.World journal of microbiology & biotechnology · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Effect of Ocular Hypertension on D-Journal of ophthalmology · 2019
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Sanaz AfraeiDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Antimo D'AnielloLaboratory of Neurobiology, Zoological Station of Naples "Anton Dohrn", Villa Comunale, Napoli, Italy.
Reza SedaghatDepartments of Anatomy and Pathology, Faculty of Medicine, Shahed University, Tehran, Iran.
Parvin EkhtiariDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Gholamreza AziziImam Hassan Mojtaba Hospital, Alborz University of Medical Sciences, Karaj, Iran.
Nakisa TabrizianDepartment of Cellular and Molecular Biology, Kish International Campus, University of Tehran, Tehran, Iran.
Laura MagliozziDepartment of Biology, University of Naples, "Federico II" Via Cinthia, MSA Campus, bldg. 7, Naples, Italy.
Zahra AghazadehDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Abbas MirshafieyDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRAlborz University of Medical SciencesShahed University · IRStazione Zoologica Anton Dohrn · ITUniversity of Naples Federico II · ITUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis. EAE is mainly mediated by adaptive and innate immune responses that leads to an inflammatory demyelization and axonal damage. The aim of the present research was to examine the therapeutic efficacy of D-aspartic acid (D-Asp) on a mouse EAE model. EAE induction was performed in female C57BL/6 mice by myelin 40 oligodendrocyte glycoprotein (35-55) in a complete Freund's adjuvant emulsion, and D-Asp was used to test its efficiency in the reduction of EAE. During the course of study, clinical evaluation was assessed, and on Day 21, post-immunization blood samples were taken from the heart of mice for the evaluation of interleukin 6 and other chemical molecules. The mice were sacrificed, and their brain and cerebellum were removed for histological analysis. Our findings indicated that D-Asp had beneficial effects on EAE by attenuation in the severity and delay in the onset of the disease. Histological analysis showed that treatment with D-Asp can reduce inflammation. Moreover, in D-Asp-treated mice, the serum level of interleukin 6 was significantly lower than that in control animals, whereas the total antioxidant capacity was significantly higher. The data indicates that D-Asp possess neuroprotective property to prevent the onset of the multiple sclerosis.

Indexed as

Multiple SclerosisAnimalsAspartic AcidD-Aspartic AcidFemaleMiceMice, Inbred C57BLMyelin-Oligodendrocyte GlycoproteinAspartic AcidD-Aspartic AcidMyelin-Oligodendrocyte GlycoproteinantioxidantD-aspartateD-aspartic acidexperimental autoimmune encephalomyelitismultiple sclerosis

Identifiers

PMID28911655
PMCPMC9328824
OpenAlexW2601314582

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.